Compare Amgen, Inc. (AMGN) vs Celsius Holdings, Inc. (CELH) Price & Performance

Amgen, Inc.Trade

Celsius Holdings, Inc.Trade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Celsius Holdings, Inc. — how do they compare? Amgen, Inc. trades at $414.76 (market cap $224.14B), while Celsius Holdings, Inc. trades at $27.1 (market cap $7.11B). The key difference: Amgen, Inc. is far larger — about 31.5× Celsius Holdings, Inc.'s market cap, and Amgen, Inc. pays a 2.43% dividend while Celsius Holdings, Inc. pays none. Which is the better fit depends on your goals.

	AMGN	CELH
Market Cap	$224.14B	$7.11B
Sector	Health	Consumer Staples
52-Week High	$417.20	$64.86
52-Week Low	$271.18	$23.77
Enterprise Value	$267.45B	$8.90B
Dividend Yield	2.43%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.

Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.

Celsius Holdings, Inc.

CELH trades at $27.21, down 2.02% on the day, with technical indicators signaling a bearish trend. The company reported Q2 2026 earnings of $0.36 per share, missing estimates of $0.4139, while revenue grew 11% year-over-year. Recent news highlights leadership changes and an ongoing shareholder investigation. The stock faces pressure from slowing core-brand growth but benefits from strong analyst support and a partnership with PepsiCo.

Outlook: High growth potential via international expansion and PepsiCo distribution, but execution risks and margin pressures persist. Risks include competitive threats and delayed growth projections. Analyst consensus is strongly bullish with a $44.08 price target, suggesting significant upside if operational challenges are overcome.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

AMGN

BioCryst hits profitability with strong Q2 revenue, sparking takeover interest in rare disease biotech.24/7 Wall Street · 1 day agoBullish View details →

CELH

Celsius core brand revenue drops 12% in Q2, prompting investigation over possible misleading disclosures.PRNewsWire · 1 day agoBearish Celsius Holdings seen as a prime beverage buyout target amid 39% YTD stock drop24/7 Wall Street · 2 days agoNeutral Celsius Holdings shares trade at a discount despite strong sales growth and activist pressure for leadership change.Seeking Alpha · 3 days agoBearish View details →

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

About Celsius Holdings, Inc.

Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.